Workflow
Will CorMedix's DefenCath Edge Last If Bigger Heparin Rivals Close In?
CorMedixCorMedix(US:CRMD) ZACKS·2025-10-07 15:36

Key Takeaways CorMedix's DefenCath is the first FDA-approved antimicrobial catheter lock solution in the U.S. market.Pfizer and Amphastar's heparin products pose potential future competition to CRMD's CRBSI market position.The $300M Melinta deal adds seven drugs, expanding CorMedix's hospital and infectious disease portfolio.CorMedix’s (CRMD) lead drug, DefenCath (Taurolidine + Heparin), is currently its only marketed product that generates revenues for the company. The FDA approved CorMedix’s DefenCath in ...